Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7348 participants
OBSERVATIONAL
2025-02-04
2025-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
In-hospital Versus DAy Care Hysterectomy in Transgender Men
NCT05393583
Gynaecological Gender-affirming Surgeries
NCT06098781
Fertility Preservation in Transgender Persons: a Retrospective Look
NCT05120245
A Standardized Counseling Approach to Preoperative Education in Transmasculine Individuals Receiving Gender-affirming Surgery
NCT07324967
Gynaecological Care for Transgender People in France in 2024.
NCT06357130
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transgender male
Hysterectomy
CPT:1013911
Transgender female
Orchiectomy
CPT:54520
Augmentation mammoplasty
CPT:19325
Cisgender male
Orchiectomy
CPT:54520
Cisgender female
Hysterectomy
CPT:1013911
Augmentation mammoplasty
CPT:19325
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orchiectomy
CPT:54520
Hysterectomy
CPT:1013911
Augmentation mammoplasty
CPT:19325
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion:
\- Patients who had malignant neoplasm of the uterus, ovarian, cervical, endometrium, or adnexa.
Transgender Male Group
Inclusion:
* administered testosterone within 6 months and 1 day before their hysterectomy
* have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
Cisgender Female Group
Inclusion:
\- identified as female.
Exclusion:
* administered testosterone within 6 months and 1 day before their hysterectomy
* have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
Orchiectomy Cohort:
Inclusion:
\- patients underwent an orchiectomy.
Exclusion:
\- history of malignant neoplasm of the testis, malignant neoplasm of the prostate, Fournier gangrene, or vascular disorders of male genital organs
Transgender Female Group
Inclusion:
* administered estrogen within 6 months and 1 day before their orchiectomy
* have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
Cisgender Male Group
Inclusion:
\- identified as male.
Exclusion:
* administered estrogen within 6 months and 1 day before their orchiectomy
* have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
Augmentation Mammoplasty:
Inclusion:
\- underwent augmentation mammoplasties.
Exclusion:
\- Have diagnosis of malignant neoplasm of the breast .
Transgender Female Group
Inclusion:
* administered estrogen within 6 months and 1 day before their augmentation mammoplasty
* have one of the following diagnoses: personal history of sex reassignment, gender identity disorder, or transsexualism.
Cisgender Female Group
Inclusion:
\- Identified as female
Exclusion:
* administered estrogen within 6 months and 1 day before their hysterectomy
* have one of the following diagnoses: personal history of sex reassignment, gender identity disorders, or transsexualism.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Riverside University Health System Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher Baker
Research Coordinator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Riverside University Health System Medical Center
Moreno Valley, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PONV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.